Back

Beactica starts IND-enabling studies for BEA-17 glioblastoma therapy

Verifying
  • Beactica Therapeutics began IND-enabling studies for its BEA-17 glioblastoma drug candidate.
  • EUR 2.5 million supports the 30-month GLIOBREAK project under Horizon Europe.
  • Beactica expects to submit EU and/or U.S. clinical applications in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.